We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
130 own
73 watching
Current Price
$81.13
$0.25
(0.31%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
172,495.39M
52-Week High
81.435
52-Week Low
55.76
Average Volume
6.37M
Dividend Yield
0.032969
P/E Ratio
16.83
Market Capitalization172,495.39M
52-Week High81.435
52-Week Low55.76
Average Volume6.37M
Dividend Yield0.032969
P/E Ratio16.83
What does the Stockal+Disclaimer.pdf do?
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers chemically-synthesized drug and biologic in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology comprising human immunodeficiency virus infection (HIV). Its products include Empliciti, a humanized monoclonal antibody to treat multiple myeloma; Opdivo, a human monoclonal antibody to treat renal cell carcinoma, non-small cell lung cancer, classical Hodgkin lymphoma, gastric cancer, melanoma, metastatic urothelial carcinoma, and squamous cell carcinoma of the head and neck; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; and Yervoy, a monoclonal antibody for metastatic melanoma. The company's products also comprise Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation; Baraclude to treat chronic hepatitis B virus; Daklinza and Sunvepra to treat hepatitis C virus (HCV); Reyataz and Sustiva to treat HIV; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; and Orencia to treat rheumatoid arthritis. It has collaborations with Portola Pharmaceuticals, Inc. to develop and commercialize andexanet alfa, an investigational agent; Apexigen, Inc. to evaluate Opdivo in combination with APX005M in patients with solid tumors; and license agreement with Nitto Denko Corporation to develop and commercialize siRNA molecules targeted at HSP47 in vitamin A. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
PR Newswire
2days ago
Optimism Building for Advancing Pancreatic Cancer Treatment Therapies Optimism Building for Advancing Pancreatic Cancer Treatment Therapies PR Newswire PALM BEACH, Fla., Dec. 1, 2022 PALM BEACH, Fla., Dec. 1, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Pancreatic cancer accounts...
PR Newswire
4days ago
Envisagenics Announces Research Collaboration with Bristol Myers Squibb Envisagenics Announces Research Collaboration with Bristol Myers Squibb PR Newswire NEW YORK, Nov. 29, 2022 Collaboration will leverage Envisagenics' SpliceCore AI platform for accelerated discovery and development of oncology...
PR Newswire
19days ago
Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies PR Newswire VANCOUVER, British Colombia, Nov. 14, 2022 FN Media Group Presents USA News Group News Commentary...
FT.com - Health Care
20days ago
US drugs maker also says low pricing of NHS purchases risks harming Britains push in life sciences...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$81.13
$0.25
(0.31%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00